Australian Clinical Labs Ltd
ASX:ACL
Intrinsic Value
Australian Clinical Labs Ltd. provides pathology services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ACL.
Australian Clinical Labs Ltd's market capitalization is 499.2m AUD.
ACL stock price is 2.49 AUD.
ACL.
ACL. Open DCF Valuation
ACL. Open Relative Valuation
ACL has upside potential of 24% compared to the average analyst price target.
Open Wall St Estimates
ACL's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
ACL has positive Net Income for the last twelve months.
ACL's D/E (Debt to Equity) is equal to 1.25.
ACL's ROE (Return on Equity) for the past 12 months is positive and is equal to 18%.
ACL's long-term assets (579m AUD) exceed its long-term liabilties (407m AUD).
ACL has positive Operating Income for the last twelve months.
ACL's Revenue is forecast to fall at a rate of 10% per year over the next 3 years.
ACL's Revenue has dropped by 30% over the past 12 months.
ACL has very high three-year average ROIC (Return on Invested Capital): 27%. The company is very efficient at using invested capital to generate operating income.
ACL's short-term liabilties (188m AUD) exceed its short-term assets (116m AUD).
ACL has positive Free Cash Flow for the last twelve months.
ACL has positive Gross Profit for the last twelve months.
ACL has positive Net Debt. This means that the company has more debt (215m AUD) than cash and short-term investments (26m AUD).
ACL's Altman Z-Score is very low and is equal to 0.89.
ACL has very high three-year average ROE (Return on Equity): 112%. The company is very efficient at transforming stockholders' equity into net income.
ACL doesn't generate enough operating income (65m AUD) to safely cover interest payments on its debt (-14m AUD).
Fundamental Analysis
Australian Clinical Labs Ltd
Balance Sheet Decomposition
Australian Clinical Labs Ltd
| Current Assets | 116m |
| Cash & Short-Term Investments | 26m |
| Receivables | 73.7m |
| Other Current Assets | 16.3m |
| Non-Current Assets | 462.9m |
| Long-Term Investments | 1.1m |
| PP&E | 288.4m |
| Intangibles | 165.2m |
| Other Non-Current Assets | 8.2m |
| Current Liabilities | 187.9m |
| Accounts Payable | 41.4m |
| Other Current Liabilities | 146.5m |
| Non-Current Liabilities | 218.6m |
| Long-Term Debt | 215.2m |
| Other Non-Current Liabilities | 3.4m |
Earnings Waterfall
Australian Clinical Labs Ltd
|
Revenue
|
697.1m
AUD
|
|
Cost of Revenue
|
-126.1m
AUD
|
|
Gross Profit
|
571m
AUD
|
|
Operating Expenses
|
-506.3m
AUD
|
|
Operating Income
|
64.7m
AUD
|
|
Other Expenses
|
-28.8m
AUD
|
|
Net Income
|
35.9m
AUD
|
Free Cash Flow Analysis
Australian Clinical Labs Ltd
ACL Profitability Score
Profitability Due Diligence
Australian Clinical Labs Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Australian Clinical Labs Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
ACL Solvency Score
Solvency Due Diligence
Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Score
Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACL Price Targets Summary
Australian Clinical Labs Ltd
According to Wall Street analysts, the average 1-year price target for
ACL
is 3.09 AUD
with a low forecast of 2.58 AUD and a high forecast of 3.52 AUD.
Shareholder Return
ACL Price
Australian Clinical Labs Ltd
| Average Annual Return | 16.95% |
| Standard Deviation of Annual Returns | 91% |
| Max Drawdown | -56% |
| Market Capitalization | 499.2m AUD |
| Shares Outstanding | 201 834 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Australian Clinical Labs Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Australian Clinical Labs Ltd. provides pathology services. The company is headquartered in Melbourne, Victoria and currently employs 2,794 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in private hospital pathology businesses in regions of Western Australia, Victoria, South Australia and the Northern Territory. Its brands include Australian Clinical Labs, SunDoctors, Helix Pathology, Southern Sun, BeFunctional Labs and Gribbles Veterinary Pathology. The Australian Clinical Labs provides pathology in Australia, servicing clinicians, patients, hospitals, commercial clients and public organizations. The SunDoctors offers diagnosis and treatment of skin cancer. The Helix Pathology delivers specialized histopathology and cytology testing services. The Southern Sun is the skin cancer lab and the commercial lab in Australia. The BeFunctional Labs assists practitioners in the diagnosis, treatment and management of patients by providing functional pathology tests. The Gribbles Veterinary Pathology provides animal health professionals with pathology service.
You don't have any saved screeners yet
